Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Prospective Controlled Study of the Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC

NCT04212273 is registered in ClinicalTrials.gov with Tianjin Third Central Hospital as lead sponsor.

NCT NCT04212273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04212273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Prospective Controlled Study of the Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC
Lead sponsor
Tianjin Third Central Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
December 21, 2019
Completion date
December 24, 2022
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diagnoses disease, hepatocellular cancer, liver cirrhoses